Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29410377 | 1.00 | MAPT (0.61) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL17931668 | 0.83 | NPC1 (0.51) | MAPTALDH1A1LMNAPOLBHPGD | |
| SCHEMBL31162452 | 0.83 | NPC1 (0.51) | MAPTALDH1A1LMNAPOLBHPGD | |
| SCHEMBL2093176 | 0.82 | MAPT (0.69) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL10477308 | 0.82 | MMP1 (0.60) | MAPTLMNAKDM4EHPGD | |
| SCHEMBL30452125 | 0.82 | MMP1 (0.60) | MAPTLMNAKDM4EHPGD | |
| SCHEMBL7191119 | 0.81 | BTK (0.49) | MAPTALDH1A1LMNAPOLBTRPV1 | |
| SCHEMBL8512135 | 0.81 | MMP1 (0.58) | KDM4EHPGD | |
| SCHEMBL6474649 | 0.81 | MAPT (0.67) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL952943 | 0.81 | MAPT (0.58) | MAPTALDH1A1LMNAPOLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466789-A | Synthesis method of beta-trifluoromethylthioamide participated by silver trifluormethane | 陕西先氟领创科技有限公司 | 2024-01-30 | — | — | CN | claimed |
| US-12630516-B2 | Compounds | NRG THERAPEUTICS LTD. (GB) | 2026-05-19 | — | — | US | disclosed |
| US-12497359-B2 | Acrylamide derivatives | NRG THERAPEUTICS LTD (GB) | 2025-12-16 | — | — | US | disclosed |
| EP-4208442-B1 | MPTP INHIBITORS | NRG THERAPEUTICS LTD (GB) | 2025-10-22 | — | — | EP | disclosed |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2025-06-05 | — | — | US | disclosed |
| EP-4208448-B1 | ACRYLAMIDE DERIVATIVES | NRG THERAPEUTICS LTD (GB) | 2025-04-23 | — | — | EP | disclosed |
| EP-4486721-A1 | ACRYLAMIDE COMPOUNDS | NRG Therapeutics LTD (GB) | 2025-01-08 | — | — | EP | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20240067614-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD. (GB) | 2024-02-29 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| US-20230312466-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-10-05 | — | — | US | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023166303-A1 | ACRYLAMIDE COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2023-09-07 | — | — | WO | disclosed |
| EP-4208442-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| EP-4208448-A1 | NOVEL COMPOUNDS | NRG Therapeutics LTD (GB) | 2023-07-12 | — | — | EP | disclosed |
| CN-116096705-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116096712-A | Novel compounds | NRG治疗有限公司 | 2023-05-09 | — | — | CN | disclosed |
| WO-2022049376-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022049377-A1 | NOVEL COMPOUNDS | NRG THERAPEUTICS LTD (GB) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630516-B2 | Compounds | CYP4B1, CYP1B1, NR4A1 | MAPT 2453/4885ALDH1A1 87/4885LMNA 1708/4885 |
| US-20230312466-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, UGT1A1 | MAPT 2537/4885ALDH1A1 516/4885LMNA 3307/4885 |
| US-20240067614-A1 | NOVEL COMPOUNDS | CYP11B1, CYP11B2, CXCR2 | MAPT 2596/4885ALDH1A1 478/4885LMNA 3273/4885 |
| US-20250179028-A1 | ACRYLAMIDE COMPOUNDS | ACR, CCNI, FANCI | MAPT 1371/4885ALDH1A1 63/4885LMNA 1086/4885 |
| US-12497359-B2 | Acrylamide derivatives | ACR, GSTA2, GSTA1 | MAPT 1784/4885ALDH1A1 48/4885LMNA 1162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.